A non-interventional, multicentre, prospective, parallel study analysing safety and efficacy of secukinumab and conventional systemics in a real world clinical setting
Latest Information Update: 24 Jan 2022
At a glance
- Drugs Secukinumab (Primary) ; Antipsoriatics
- Indications Plaque psoriasis
- Focus Adverse reactions; Therapeutic Use
- Acronyms REALIA
Most Recent Events
- 24 Jan 2022 New trial record
- 17 Jan 2022 Results published in the Dermatology and Therapy